Aldeyra Therapeutics, Inc.
NASDAQ:ALDXBiotechnology
+$0.06 today
- Market cap
- $54.28M
- Beta
- 1.19
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$0.45
Volume 1.45M
Average 2.13M
ALDX Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Aldeyra Therapeutics, Inc.NASDAQ: ALDX
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development declines year over year
Q1 FY2026 research & development of $2.41M fell 67.5% year over year, behind the -58.3% change in trailing-twelve-month research & development. Sequentially, it fell 44.0% from the prior quarter. Over 3 fiscal years it compounded at -18.4% a year.
Context
- Research & development increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -67.5% toward the trailing-twelve-month pace of -58.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 25.66M USD
- Year-over-year change
- -46.8%
- 4-year CAGR
- -13.1%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 25.66M | -46.8% |
| FY2024 | 2024-12-31 | 48.22M | +63.7% |
| FY2023 | 2023-12-31 | 29.46M | -37.7% |
| FY2022 | 2022-12-31 | 47.31M | +5.3% |
| FY2021 | 2021-12-31 | 44.94M | — |
Research & Development vs competitors
How ALDX compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -58.3% is the lowest of 10, against a peer median of +3.6%.
- Over three fiscal years its annual growth of -18.4% compares with a peer median of +18.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $126.01M USD | -0.7% | +67.6% | — | |
| LTM Mar 2026 | $94.68M USD | +5.0% | -1.4% | 139.0% | |
| LTM Mar 2026 | $61.84M USD | — | +24.0% | 6710.8% | |
| LTM Mar 2026 | $55.94M USD | +19.0% | +24.4% | — | |
| LTM Mar 2026 | CHF 52.18M CHF | -17.6% | -2.2% | 1409.6% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $49.38M USD | +11.3% | +45.0% | — |
| LTM Mar 2026 | $36.32M USD | +88.9% | +13.6% | — | |
| LTM Mar 2026 | $20.65M USD | -58.3% | -18.4% | — | |
GNLXGenelux Corporation | LTM Mar 2026 | $20.4M USD | +3.6% | +29.8% | 254962.5% |
| LTM Mar 2026 | $18.45M USD | -6.9% | -13.3% | 8.6% | |
| LTM Mar 2026 | $18.13M USD | -12.8% | -16.7% | 3625.8% | |
| Peer median (excluding ALDX) | — | +3.6% | +18.8% | 2517.7% | |
Competitors are the stored peer set for ALDX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 44.94M | 47.31M | 29.46M | 48.22M | 25.66M |
| Selling, General & Admin | 11.28M | 15.37M | 13.34M | 11.89M | 9.6M |
| Operating Expenses | 56.22M | 62.68M | 42.79M | 60.12M | 35.27M |
| Depreciation & Amortization | 264.18K | 258.71K | 262.78K | 249.62K | 251.99K |
| EBITDA | (55.77M) | (60.07M) | (35.21M) | (53.68M) | (31.69M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (56.22M) | (62.68M) | (42.79M) | (60.12M) | (35.27M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 185.36K | 2.35M | 7.32M | 6.19M | 3.32M |
| Interest Expense | 1.74M | 1.69M | 2.07M | 1.93M | 1.91M |
| Other Income / Expenses | (1.56M) | 655.35K | 5.25M | 4.27M | 1.42M |
| Income Before Tax | (57.78M) | (62.02M) | (37.54M) | (55.85M) | (33.85M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (57.78M) | (62.02M) | (37.54M) | (55.85M) | (33.85M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.07) | (1.06) | (0.64) | (0.94) | (0.56) |
| EPS (Diluted) | (1.07) | (1.06) | (0.64) | (0.94) | (0.56) |
| Weighted Avg Shares | 54.04M | 58.41M | 58.94M | 59.48M | 60.06M |
| Weighted Avg Shares (Diluted) | 54.04M | 58.41M | 58.94M | 59.48M | 60.06M |
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.